{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:06:35Z","timestamp":1792184795323,"version":"4.4.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"787","license":[{"start":{"date-parts":[[1991,5,1]],"date-time":"1991-05-01T00:00:00Z","timestamp":673056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1991,5,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Thyrotrophin secreting pituitary adenomas are a rare cause of recurrent thyrotoxicosis. We report on a 47 year old woman with an 8-year history of this condition. In this case the somatostatin analogue, octreotide, normalized thyroid hormone levels. It was associated with marked tumour shrinkage, with striking reduction of the suprasellar extension and improved appearances in the region of the left cavernous sinus shown by high resolution computerized tomography. Following surgery she developed a biochemical relapse which responded to the reinstitution of octreotide. On long term treatment she developed stomach cramps and gallstones. Octreotide was discontinued. We review previous reports of this condition and discuss the role of octreotide in its management.<\/jats:p>","DOI":"10.1136\/pgmj.67.787.466","type":"journal-article","created":{"date-parts":[[2008,12,29]],"date-time":"2008-12-29T21:01:03Z","timestamp":1230584463000},"page":"466-468","source":"Crossref","is-referenced-by-count":7,"title":["Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide"],"prefix":"10.1093","volume":"67","author":[{"given":"S M","family":"Orme","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The General Infirmary at Leeds , Great George Street, Leeds LS1 3EX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J T","family":"Lamb","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, The General Infirmary at Leeds , Great George Street, Leeds LS1 3EX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, The General Infirmary at Leeds , Great George Street, Leeds LS1 3EX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P E","family":"Belchetz","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The General Infirmary at Leeds , Great George Street, Leeds LS1 3EX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[1991,5,1]]},"reference":[{"key":"ref_1","first-page":"575","article-title":"Thyrotrophin producing pituitary adenomas","volume":"57","author":"Hill, S.A.; Falko, J.M.; Wilson, C.B.; Hunt, W.E.","year":"1982","unstructured":"Hill, S.A., Falko, J.M., Wilson, C.B. & Hunt, W.E. Thyrotrophin producing pituitary adenomas. J Neurosurg 1982, 57: 575-579.","journal-title":"J Neurosurg"},{"issue":"12","key":"ref_2","first-page":"396","article-title":"Neuroendocrine control of thyrotrophin secretion","volume":"1981","author":"Morley, J.E.","unstructured":"Morley, J.E. Neuroendocrine control of thyrotrophin secretion. Endocrinol Rev 1981, 12: 396-436.","journal-title":"Endocrinol Rev"},{"issue":"95","key":"ref_3","first-page":"339","article-title":"Inappropriate secretion of thyroid-stimulating hormone","volume":"1981","author":"Weintraub, B.D.; Gershengorn, M.D.; Kourides, I.A.; Fien, H.","unstructured":"Weintraub, B.D., Gershengorn, M.D., Kourides, I.A. & Fien, H. Inappropriate secretion of thyroid-stimulating hormone. Ann Intern Med 1981, 95: 339-351.","journal-title":"Ann Intern Med"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/0003-4819-110-1-35","article-title":"Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone secreting tumours of the pituitary gastrointestinal tract and non-neoplastic diseases of the gut","volume":"110","author":"Gorden, P.; Comi, R.J.; Maton, P.N.; Go, V.W.","year":"1989","unstructured":"Gorden, P., Comi, R.J., Maton, P.N. & Go, V.W. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone secreting tumours of the pituitary gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989, 110: 35-50.","journal-title":"Ann Intern Med"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJM197208172870704","article-title":"Hyperthyroidism and excessive thyrotrophin secretion","volume":"287","author":"Emerson, C.H.; Utiger, R.D.","year":"1972","unstructured":"Emerson, C.H. & Utiger, R.D. Hyperthyroidism and excessive thyrotrophin secretion. N Engl J Med 1972, 287: 328-333.","journal-title":"N Engl J Med"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1172\/JCI108133","article-title":"Thyrotrophin induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone","volume":"56","author":"Gershengorn, M.C.; Weintraub, B.D.","year":"1975","unstructured":"Gershengorn, M.C. & Weintraub, B.D. Thyrotrophin induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. J Clin Invest 1975, 56: 633-642.","journal-title":"J Clin Invest"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1210\/jcem-43-3-575","article-title":"Familial target organ resistance to thyroid hormones","volume":"43","author":"Elewaut, A.; Mussche, M.; Vermeulen, A.","year":"1976","unstructured":"Elewaut, A., Mussche, M. & Vermeulen, A. Familial target organ resistance to thyroid hormones. J Clin Endocrinol Metab 1976, 43: 575-581.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1210\/jcem-45-3-534","article-title":"Thyrotrophin-induced hyperthyroidism use of alpha and beta subunit levels to identify patients with tumours","volume":"45","author":"Kourides, I.A.; Ridgway, E.C.; Weintraub, B.D.","year":"1977","unstructured":"Kourides, I.A., Ridgway, E.C., Weintraub, B.D. et al. Thyrotrophin-induced hyperthyroidism use of alpha and beta subunit levels to identify patients with tumours. J Clin Endocrinol Metabol 1977, 45: 534-543.","journal-title":"J Clin Endocrinol Metabol"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1210\/jcem-45-5-903","article-title":"Endocrine and morphologic studies of pituitary adenomas secondary to primary hyperthyroidism","volume":"45","author":"Samaan, N.A.; Osbourne, B.M.; Mackay, B.; Leavens, M.E.; Duello, T.M.; Halmi, N.S.","year":"1977","unstructured":"Samaan, N.A., Osbourne, B.M., Mackay, B., Leavens, M.E., Duello, T.M. & Halmi, N.S. Endocrine and morphologic studies of pituitary adenomas secondary to primary hyperthyroidism. J Clin Endocrinol Metab 1977, 45: 903-911.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref_10","first-page":"59","article-title":"of two thyrotrophin secreting pituitary adenomas evidence for dopamine receptor deficiency","volume":"31","author":"Bevan, J.S.; Burke, C.W.; Esiri, M.M.","year":"1989","unstructured":"Bevan, J.S., Burke, C.W., Esiri, M.M. et al. Studies of two thyrotrophin secreting pituitary adenomas evidence for dopamine receptor deficiency. Clin Endocrinol 1989, 31: 59-70.","journal-title":"et al. Studies"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/archinte.1983.00350030117019","article-title":"Hyperthyroidism due to thyrotrophin secreting pituitary tumours, diagnostic and therapeutic considerations","volume":"143","author":"Smallbridge, R.C.; Smith, C.E.","year":"1983","unstructured":"Smallbridge, R.C. & Smith, C.E. Hyperthyroidism due to thyrotrophin secreting pituitary tumours, diagnostic and therapeutic considerations. Arch Intern Med 1983, 143: 503-507.","journal-title":"Arch Intern Med"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1056\/NEJM198707023170103","article-title":"Response of thyrotrophin secreting pituitary adenomas to a long acting SMS-analogue","volume":"317","author":"Comi, R.J.; Gesundheit, N.; Murray, L.; Gorden, P.; Weintraub, B.D.","year":"1987","unstructured":"Comi, R.J., Gesundheit, N., Murray, L., Gorden, P. & Weintraub, B.D. Response of thyrotrophin secreting pituitary adenomas to a long acting SMS-analogue. N Engl J Med 1987, 317: 12-17.","journal-title":"N Engl J Med"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1210\/jcem-68-1-208","article-title":"Treatment of hyperthyroidism due to inappropriate secretion of thyrotrophin with somatostatin analogue SMS 201-995","volume":"68","author":"Beck-Peccoz, P.; Mariotti, S.; Guillausseau, P.J.","year":"1989","unstructured":"Beck-Peccoz, P., Mariotti, S., Guillausseau, P.J. et al. Treatment of hyperthyroidism due to inappropriate secretion of thyrotrophin with somatostatin analogue SMS 201-995. J Clin Endocrinol Metab 1989, 68: 208-214.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJM198707023170113","article-title":"Visual improvement with SMS 201-995 in a patient with a thyrotrophin secreting pituitary adenoma","volume":"317","author":"Guillausseau, P.J.; Chanson, P.H.; Timsit, J.","year":"1987","unstructured":"Guillausseau, P.J., Chanson, P.H. & Timsit, J. Visual improvement with SMS 201-995 in a patient with a thyrotrophin secreting pituitary adenoma. NEnglJ Med 1987, 317: 53-54.","journal-title":"NEnglJ Med"},{"issue":"67","key":"ref_15","first-page":"1040","article-title":"Preoperative treatment with long acting somatostatin analogue SMS 201-995, shrinkage of invasive pituitary macroadenomas and improved surgical remission rate","volume":"1988","author":"Barkan, A.L.; Lloyd, R.V.; Chandler, W.F.","unstructured":"Barkan, A.L., Lloyd, R.V., Chandler, W.F. et al. Preoperative treatment with long acting somatostatin analogue SMS 201-995, shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988, 67: 1040-1048.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM197908093010601","article-title":"Somatostatinoma syndrome, biochemical, morphologic and clinical features","volume":"301","author":"Krejs, G.J.; Orci, L.; Conlon, J.M.","year":"1979","unstructured":"Krejs, G.J., Orci, L., Conlon, J.M. et al. Somatostatinoma syndrome, biochemical, morphologic and clinical features. N Engi J Med 1979, 301: 285-292.","journal-title":"N Engi J Med"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/67\/787\/466\/50075297\/postgradmedj-67-466.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/67\/787\/466\/50075297\/postgradmedj-67-466.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T16:24:17Z","timestamp":1682612657000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/67\/787\/466\/7061704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,5,1]]},"references-count":16,"journal-issue":{"issue":"787","published-online":{"date-parts":[[1991,5,1]]},"published-print":{"date-parts":[[1991,5,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.67.787.466","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1991,5]]},"published":{"date-parts":[[1991,5,1]]}}}